Exelixis Inc
NASDAQ: EXEL
$36.21
+$0.60 (+1.7%)
Real Time Data Delayed 15 Min.
EXEL Articles
SeaChange, Sears, Exelixis, and Adamis Pharma all posted new 52-week lows Tuesday.
Published:
Last Updated:
Lannett Co., Scorpio Tankers, Mobile Telesystems, and Exelixis all posted new 52-week lows Monday.
Published:
Last Updated:
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.
Published:
Last Updated:
The include Albermarle, Best Buy, Chipotle Mexican Grill, Exact Sciences, Fitbit, Itron, NuVasive, Palo Alto Networks and Stryker.
Published:
Last Updated:
Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular carcinoma.
Published:
Last Updated:
Exelixis saw its shares make a handy gain on Wednesday after the company received the nod from the FDA for Cabometyx tablets.
Published:
Last Updated:
With tax reform having cleared the Senate and going back to the House, investors were looking for a higher stock market open on Wednesday.
Published:
Last Updated:
Exelixis kicked off the week with a couple updates that are already having a big impact on the stock. These updates came in the form of a key FDA approval.
Published:
Last Updated:
Some of the top biotech stocks could become extremely volatile before and after earnings. These four that may be worth a look for aggressive investors.
Published:
Last Updated:
Tuesday’s top analyst upgrades, downgrades and initiations include Apple, CVS Health, Priceline, Teva Pharmaceutical and Workday.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Published:
Last Updated:
Shares of Exelixis saw a handy gain early Monday morning after the company reported positive results from its mid-stage trial for the treatment of renal cell carcinoma.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-stage to late-stage trials that should be announced in October.
Published:
Last Updated:
24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Published:
Last Updated: